DK2435583T3 - miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI - Google Patents

miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI

Info

Publication number
DK2435583T3
DK2435583T3 DK10723982T DK10723982T DK2435583T3 DK 2435583 T3 DK2435583 T3 DK 2435583T3 DK 10723982 T DK10723982 T DK 10723982T DK 10723982 T DK10723982 T DK 10723982T DK 2435583 T3 DK2435583 T3 DK 2435583T3
Authority
DK
Denmark
Prior art keywords
duchennes
mir
treatment
muscle
drops
Prior art date
Application number
DK10723982T
Other languages
English (en)
Inventor
Irene Bozzoni
Julie Martone
Davide Cacchiarelli
Tania Incitti
Original Assignee
Universit Degli Studi Di Roma La Sapienza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20090161038 external-priority patent/EP2258863A1/en
Application filed by Universit Degli Studi Di Roma La Sapienza filed Critical Universit Degli Studi Di Roma La Sapienza
Application granted granted Critical
Publication of DK2435583T3 publication Critical patent/DK2435583T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK10723982T 2009-05-25 2010-05-24 miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI DK2435583T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20090161038 EP2258863A1 (en) 2009-05-25 2009-05-25 miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
PCT/EP2010/057093 WO2010136417A1 (en) 2009-05-25 2010-05-24 miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY

Publications (1)

Publication Number Publication Date
DK2435583T3 true DK2435583T3 (da) 2014-09-29

Family

ID=40718989

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10723982T DK2435583T3 (da) 2009-05-25 2010-05-24 miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI

Country Status (4)

Country Link
US (1) US9034838B2 (da)
EP (1) EP2435583B1 (da)
DK (1) DK2435583T3 (da)
WO (1) WO2010136417A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
SI3133160T1 (sl) 2008-10-24 2019-05-31 Sarepta Therapeutics, Inc. Sestavki, ki preskakujejo ekson za DMD
ES2693459T3 (es) 2009-11-12 2018-12-11 The University Of Western Australia Moléculas antisentido y métodos para el tratamiento de patologías
EP2535412A1 (en) * 2011-06-17 2012-12-19 Universitat Pompeu-Fabra New treatment for muscular dystrophies
EP3633035A1 (en) 2013-03-14 2020-04-08 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
US9637738B2 (en) 2013-04-10 2017-05-02 Reveragen Biopharma, Inc. Methods and agents to increase therapeutic dystrophin expression in muscle
EP3598978B1 (en) 2018-07-26 2024-05-29 EXOFIX S.r.l. Fibroadipogenic progenitor-derived exosomes for regeneration of dystrophic muscles
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US20100202973A1 (en) 2007-05-18 2010-08-12 Karolinska Institutet Innovations Ab Microrna molecules associated with inflammatory skin disorders

Also Published As

Publication number Publication date
WO2010136417A1 (en) 2010-12-02
EP2435583A1 (en) 2012-04-04
US9034838B2 (en) 2015-05-19
EP2435583B1 (en) 2014-07-09
US20120129920A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
DK2435583T3 (da) miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
DK2448637T4 (da) Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi
HK1225316A1 (zh) 治療病毒感染的方法
BRPI1010197A2 (pt) métodos e compostos de pirazolopirimidina jak
IL208354A0 (en) Methods of treatment
DK2329012T3 (da) Behandling af slagtilfælde under anvendelse af isolerede placentaceller
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
EP2254597A4 (en) TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2350116T3 (da) Behandling af biofilm
DK3124610T3 (da) Hbv-behandling
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
BRPI0919127A2 (pt) métodos para tratamento de água
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
BR112014015551A8 (pt) método para tratar lama e método para desidratação de lama
BRPI0916079A2 (pt) tratamento de água marinha residual
DK2554171T3 (da) Fremgangsmåde til behandling af sygdomme
DK2501381T3 (da) Behandling af atrieflimmer
DK2297047T3 (da) Indretning til rensning af spildevand
EP2164494A4 (en) Methods of Treatment
DK2229943T3 (da) Forbindelse til anvendelse ved behandling af perifer neuropati
FI20090395A0 (fi) Kompostipuhdistamo
EP2349299A4 (en) COMPOSITION FOR THE TREATMENT OF HYPERTENSION
EP2440238A4 (en) Methods of Treatment
ES1070372Y (es) Rifle monotiro desmontable y mejorado